
Kansai Nerolac Q1 Results FY27: PAT at Rs 228 Cr for June 2026 Quarter
Kansai Nerolac Q1 results FY27: PAT Rs 228 Cr (+5.95% YoY) | Revenue Rs 2,373 Cr (+9.79% YoY) | Gross Margin 11.2% | Stock Rs 202 (down 1.07%)
Updated: 4 Aug 2026 • 11:13 am
Posted by:

The Kansai Nerolac Q1 results FY27 show consolidated revenue of Rs 2,373 Cr for the quarter ended 30 June 2026, +9.79% year on year from Rs 2,162 Cr in Q1 FY26, as Kansai Nerolac reported its numbers on 4 August 2026. Kansai Nerolac posted pat of Rs 228 Cr for the quarter, against Rs 215 Cr in Q1 FY26, a change of +5.95%. Shares traded around Rs 202 on the NSE, down 1.07% on the day.
The June 2026 quarter played out against a broadly stable macro backdrop, contained inflation, a supportive monsoon outlook, and resilient domestic consumption, though global uncertainty around tariffs and commodity prices kept sector-level variability elevated. Against that backdrop, the Kansai Nerolac Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.
Click Here – Get Free Investment Predictions
Kansai Nerolac Q1 results FY27 Financial Highlights
All figures are consolidated numbers in Rs Crore as reported by Kansai Nerolac for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue | Rs 2,373 Cr | Rs 2,162 Cr | +9.79% |
| Gross Profit | Rs 265 Cr | Rs 250 Cr | +6.13% |
| Gross Profit Margin | 11.2% | 11.6% | -0.4 pts |
| Net Profit (PAT) | Rs 228 Cr | Rs 215 Cr | +5.95% |
| Net Profit Margin | 9.6% | 9.9% | -0.3 pts |
Kansai Nerolac Q1 results FY27 Performance Analysis
Kansai Nerolac managed topline stability this quarter with revenue of Rs 2,373 Cr, up +9.79% year on year from Rs 2,162 Cr. The modest pace of growth warrants a closer look at whether the company is gaining or losing share in its addressable market.
Margin pressure was visible in the Kansai Nerolac Q1 results FY27. Gross profit moved +6.13% to Rs 265 Cr (11.2% margin) from Rs 250 Cr in Q1 FY26, growing slower than revenue or contracting outright. Input costs or pricing pressure appear to be the key culprits.
The bottom line improved alongside the topline. Net profit (pat) reached Rs 228 Cr, up +5.95% from Rs 215 Cr in Q1 FY26. The earnings growth is healthy and broadly consistent with revenue growth, suggesting the business is scaling without sacrificing margin quality.
Check the Univest Screener for Live Data
Kansai Nerolac Q1 results FY27: Key Business Factors
1. Revenue: What Drove the Quarter
Kansai Nerolac reported revenue of Rs 2,373 Cr against Rs 2,162 Cr in Q1 FY26, a change of +9.79%. Understanding this revenue figure requires context: in the broader market, volume growth and realisation per unit are both drivers, and the aggregate revenue number is the product of both. Investors tracking Kansai Nerolac should check the investor presentation or earnings call commentary for the volume-versus-pricing split underlying this quarter's topline.
2. Gross Profit and Margin Trends
Gross margin was broadly stable at 11.2% versus 11.6% in Q1 FY26. Stability in this line is a credible outcome for the broader market, where input cost movements, demand cyclicality and competitive intensity can move margins sharply quarter to quarter. Sustained gross margin stability gives management a predictable base to work from as it invests in growth for the rest of FY27.
3. Net Profit and Earnings Quality
Kansai Nerolac posted pat of Rs 228 Cr for the June 2026 quarter, against Rs 215 Cr in Q1 FY26, a change of +5.95%. This bottom line figure is what drives earnings per share and, ultimately, the P/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.
Kansai Nerolac Q1 results FY27 vs Analyst Expectations
Analyst estimates for the Kansai Nerolac Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 2,373 Cr and PAT of Rs 228 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking Kansai Nerolac should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.
Kansai Nerolac Dividend Update
No specific dividend announcement was confirmed as part of the Kansai Nerolac Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking Kansai Nerolac for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.
Kansai Nerolac Outlook After Q1 results FY27
The Kansai Nerolac Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 2,373 Cr and PAT at Rs 228 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the growth in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter's gross profit margin of 11.2% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the broader market through the rest of the year.
Investors tracking Kansai Nerolac after the Q1 FY27 numbers should focus on three things heading into Q2 FY27: whether the growth in revenue sustains, whether the improvement trend in profit continues without the help of one-off items, and whether management's guidance for FY27 holds. A results conference call or investor presentation, if scheduled, will be the primary opportunity for management to address these questions.
Should You Buy Kansai Nerolac After the Q1 results FY27?
The question most investors ask after any quarterly result is whether it changes the investment case. The Kansai Nerolac Q1 results FY27 show revenue of Rs 2,373 Cr, gross profit of Rs 265 Cr, and PAT of Rs 228 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 202 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.
Kansai Nerolac Share Price After the Q1 results FY27
Kansai Nerolac shares traded at Rs 202 on the NSE, down 1.07% on the day the Kansai Nerolac Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for Kansai Nerolac are available on the Univest Screener for investors who want to time their entry or exit.
Download the Univest iOS App or Univest Android App to track Kansai Nerolac live share price and upcoming quarterly results.
Key Risks to Track After the Kansai Nerolac Q1 results FY27
Investors should weigh these risks carefully before acting on the Q1 data.
1. Sector and Margin Risk
Kansai Nerolac operates in the broader market, which is exposed to input cost movements, demand cyclicality and competitive intensity. A reversal of the trends visible in the Kansai Nerolac Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.
2. Single-Quarter vs Trend Risk
A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The Kansai Nerolac Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.
3. Macro and External Risk
Macro factors including RBI rate decisions, INR/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the broader market faster than company-level actions can compensate for.
Conclusion
The Kansai Nerolac Q1 results FY27 show consolidated revenue of Rs 2,373 Cr (+9.79% year on year) and PAT of Rs 228 Cr (versus Rs 215 Cr in Q1 FY26). Gross profit came in at Rs 265 Cr at a margin of 11.2%, improving from Rs 250 Cr a year earlier. Revenue growth and a stronger bottom line were the two key themes of the quarter. Investors tracking Kansai Nerolac should use the Kansai Nerolac Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Kansai Nerolac Q1 results FY27
What were the Kansai Nerolac Q1 results FY27?
Ans. Kansai Nerolac reported revenue of Rs 2,373 Cr (+9.79% YoY) and PAT of Rs 228 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 215 Cr in Q1 FY26.
What is the PAT in the Kansai Nerolac Q1 results FY27?
Ans. PAT in the Kansai Nerolac Q1 results FY27 stood at Rs 228 Cr, compared with Rs 215 Cr in Q1 FY26, a change of +5.95%.
What was the revenue in the Kansai Nerolac Q1 results FY27?
Ans. Revenue in the Kansai Nerolac Q1 results FY27 was Rs 2,373 Cr, a change of +9.79% from Rs 2,162 Cr in Q1 FY26.
What was the gross profit in the Kansai Nerolac Q1 results FY27?
Ans. Gross profit in the Kansai Nerolac Q1 results FY27 was Rs 265 Cr (11.2% margin), compared with Rs 250 Cr in Q1 FY26, a change of +6.13%.
Did Kansai Nerolac declare a dividend with the Q1 results FY27?
Ans. No dividend was confirmed as part of the Kansai Nerolac Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from Kansai Nerolac.
What is the outlook for Kansai Nerolac after Q1 results FY27?
Ans. Following the Kansai Nerolac Q1 results FY27, analysts will track whether the growth in revenue and improvement in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.
Is Kansai Nerolac a good buy after Q1 results FY27?
Ans. The Kansai Nerolac Q1 results FY27 show revenue of Rs 2,373 Cr and PAT of Rs 228 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.
Recent Articles

Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 14: Full Scheme Comparison and Current Status
4 August 2026

Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 5: Full Scheme Comparison and Current Status
4 August 2026

Kotak India Growth Fund Series I vs ICICI Prudential India Recovery Fund - Series 3: Full Scheme Comparison and Current Status
4 August 2026

Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 1: Full Scheme Comparison and Current Status
4 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 14: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 5: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential India Recovery Fund - Series 3: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 1: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential Equity Savings Fund - Series 1: Full Scheme Comparison and Current Status
Popular this week
Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 14: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 5: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential India Recovery Fund - Series 3: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential Value Fund - Series 1: Full Scheme Comparison and Current Status
Kotak India Growth Fund Series I vs ICICI Prudential Equity Savings Fund - Series 1: Full Scheme Comparison and Current Status

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





